SARS-CoV-2 induces a unique mitochondrial transcriptome signature

Miller, Brendan; Silverstein, Ana R.; Flores, Melanie; Wang, Xiang; Cao, Kevin; Kumagai, Hiroshi; Mehta, Hemal H.; Yen, Kelvin; Kim, Su-Jeong; Cohen, Pinchas

doi:10.21203/rs.3.rs-36568/v1

Cited by 5 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…94 Preliminary observations suggest that SARSR-CoV-2 affects mitochondrial activity. 95 Furthermore, Wang et al also identified mitochondrial crista abnormalities in liver specimen of COVID-19 patients. 40 Interestingly, impaired mitochondrial activity has also been implicated in the pathogenesis of NAFLD/NASH.…”

Section: Sar S -Cov2 and Hepati C S Te Atos Ismentioning

confidence: 99%

“…Microvesicular steatosis is typically caused by genetic or acquired mitochondrial β‐oxidation defects 94 . Preliminary observations suggest that SARSR‐CoV‐2 affects mitochondrial activity 95 . Furthermore, Wang et al also identified mitochondrial crista abnormalities in liver specimen of COVID‐19 patients 40 .…”

Section: Sars‐cov2 and Hepatic Steatosismentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiological mechanisms of liver injury in COVID‐19

Nardo

Schneeweiss-Gleixner

Bakail

et al. 2020

Liver International

334

364

View full text Add to dashboard Cite

, the outbreak of coronavirus disease 2019 (COVID-19), caused by the novel Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV) 2 (SARS-CoV-2), has led within a few months to a major global health and economic crisis. As of October 2020, more than 40 million confirmed cases have been reported worldwide, with nearly 1 million deaths, affecting 189 countries. 1 The respiratory tract is considered the main target of SARS-CoV-2 infection and a small subset of infected individuals becomes severely ill and may develop acute respiratory distress syndrome (ARDS) with potentially fatal outcome. 2 More recently, systemic features of the disease with the involvement of organs outside the respiratory tract, including the liver and gastrointestinal tract are receiving increasing attention, indicating that COVID-19 may be considered as a systemic infectious and inflammatory disease. 3-7 Although closely related to other Corona virus (CoV) family members SARS-CoV and MERS-CoV (Middle East Respiratory Syndrome CoV), infections with the new SARS-CoV-2 exhibit a different pathological pattern and the mechanistic link between CoVs-induced molecular pathophysiological changes and clinical manifestations remains incompletely understood.

show abstract

Section: Sar S -Cov2 and Hepati C S Te Atos Ismentioning

confidence: 99%

Section: Sars‐cov2 and Hepatic Steatosismentioning

confidence: 99%

Pathophysiological mechanisms of liver injury in COVID‐19

Nardo

Schneeweiss-Gleixner

Bakail

et al. 2020

Liver International

334

364

View full text Add to dashboard Cite

show abstract

“…It is known that impaired mitochondrial activity is associated with the pathogenesis of NAFLD/NASH [119]. Based on transcriptomic analysis and ultrastructural examination, SARS-CoV-2 infection suppressed hepatic mitochondrial activity and caused obvious mitochondrial swelling of hepatocytes [55,120], strongly suggesting that SARS-CoV-2 directly causes cytopathic effects and contributes to MAFLD progression.…”

Section: Direct Cytotoxicity Of Virusmentioning

confidence: 99%

COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD

Chen¹,

Chen²

2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an ongoing global health pandemic. Since 2019, the pandemic continues to cast a long shadow on all aspects of our lives, bringing huge health and economic burdens to all societies. With our in-depth understanding of COVID-19, from the initial respiratory tract to the later gastrointestinal tract and cardiovascular systems, the multiorgan involvement of this infectious disease has been discovered. Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly named nonalcoholic fatty liver disease (NAFLD), is a major health issue closely related to metabolic dysfunctions, affecting a quarter of the world's adult population. The association of COVID-19 with MAFLD has received increasing attention, as MAFLD is a potential risk factor for SARS-CoV-2 infection and severe COVID-19 symptoms. In this review, we provide an update on the interactions between COVID-19 and MAFLD and its underlying mechanisms.

show abstract

“…Preliminary observations suggest that SARS-CoV-2 affects mitochondrial activity. 57 Furthermore, Wang et al identified mitochondrial crista abnormalities in liver specimens from COVID-19 patients. Interestingly, impaired mitochondrial activity has also been implicated in the pathogenesis of NAFLD/non-alcoholic steatohepatitis.…”

Section: Bilirubin Levelmentioning

confidence: 99%

“…Preliminary observations suggest that SARS‐CoV‐2 affects mitochondrial activity. 57 Furthermore, Wang et al. identified mitochondrial crista abnormalities in liver specimens from COVID‐19 patients.…”

Section: Pathophysiology Of Liver Involvement In Covid-19mentioning

confidence: 99%

Involvement of the Liver in COVID-19: A Systematic Review

Kariyawasam

Jayarajah

Abeysuriya

et al. 2022

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

COVID-19, a respiratory viral infection, has affected 388 million individuals worldwide as of the February 4, 2022. In this review, we have outlined the important liver manifestations of COVID-19 and discussed the possible underlying pathophysiological mechanisms and their diagnosis and management. Factors that may contribute to hepatic involvement in COVID-19 include direct viral cytopathic effects, exaggerated immune responses/systemic inflammatory response syndrome, hypoxia-induced changes, vascular changes due to coagulopathy, endothelitis, cardiac congestion from right heart failure, and drug-induced liver injury. The majority of COVID-19-associated liver symptoms are mild and self-limiting. Thus management is generally supportive. Liver function tests and abdominal imaging are the primary investigations done in relation to liver involvement in COVID-19 patients. However, imaging findings are nonspecific. Severe acute respiratory syndrome coronavirus 2 RNA has been found in liver biopsies. However, there is limited place for liver biopsy in the clinical context, as it does not influence management. Although, the management is supportive in the majority of patients without previous liver disease, special emphasis is needed in those with nonalcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma, hepatitis B and C infections, and alcoholic liver disease, and in liver transplant recipients.

show abstract

SARS-CoV-2 induces a unique mitochondrial transcriptome signature

Cited by 5 publications

References 21 publications

Pathophysiological mechanisms of liver injury in COVID‐19

Pathophysiological mechanisms of liver injury in COVID‐19

COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD

Involvement of the Liver in COVID-19: A Systematic Review

Contact Info

Product

Resources

About